Join to View Full Profile
55 Fruit St# HematoloBoston, MA 02114
Phone+1 617-724-4000
Fax+1 617-726-2894
Dr. Hock is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Mass General Brigham/Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 1996 - 1999
Icahn School of Medicine at Mount Sinai/Beth IsraelResidency, Internal Medicine, 1993 - 1996
Freie University Berlin Faculty of MedicineClass of 1989
Certifications & Licensure
MA State Medical License 1996 - 2025
American Board of Internal Medicine Hematology
Clinical Trials
- ABL001 + Dasatinib + Prednisone + Blinatumomab in BCR-ABL+ B-ALL or CML Start of enrollment: 2018 Jul 24
Publications & Presentations
PubMed
- Ixazomib in addition to chemotherapy for the treatment of acute myeloid leukemia in older adults.Philip C Amrein, Frederic I Preffer, Geoffrey Fell, Eyal C Attar, Rupa Narayan
Leukemia & Lymphoma. 2025-03-12 - 4 citationsIxazomib in addition to chemotherapy for the treatment of acute lymphoblastic leukemia in older adults.Philip Amrein, Karen Ballen, Kristen Stevenson, Andrew Brunner, Gabriela Hobbs
Leukemia & Lymphoma. 2022-06-01 - A nonrandomized phase I and biomarker trial of regorafenib in advanced myeloid malignancies.Joan How, Siyang Ren, Jennifer Lombardi-Story, Meghan Bergeron, Julia Foster
Ejhaem. 2022-05-01
Press Mentions
MGH Study Identifies First Molecular Steps to Childhood LeukemiaJuly 15th, 2009- Some Blood-System Stem Cells Reproduce More Slowly Than ExpectedDecember 5th, 2008
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
